Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report). The company’s ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

in a Sangamo Conference matchup with Pleasant Plains. “It really sucked not being able to play, but I think I worked hard to get better and I feel great.” Need a break? Play the USA TODAY ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 billion.

After hours: February 7 at 7:59:47 PM EST ...